The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities
Cytotherapy and Longevity · 17.11.2026 · 1 (2) · 1
DOI: 10.66729/cl202607005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytotherapy and Longevity, online erschienen am 17.11.2026. Verfasst von Chenyu Guo und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Population aging is accelerating worldwide, creating an urgent need to understand biological processes that influence late-life health. The gut microbiota, defined here primarily as the bacterial communities inhabiting the intestine, changes across the lifespan and may contribute to immune, metabolic, neural, and musculoskeletal phenotypes of aging. However, reported age-related microbiota signatures remain heterogeneous, reflecting differences in cohort design, sequencing strategy, functional annotation, and clinical context. In this review, we synthesize evidence from human cohorts, animal models, and mechanistic studies on the bidirectional relationship between host aging and gut microbial remodeling. A central theme is that host factors such as immune senescence, barrier dysfunction, altered gastrointestinal physiology, and medication exposure can drive microbial change. In contrast, microbial products can feed back on aging tissues. We distinguish chronological aging, healthy aging, frailty, exceptional longevity, and age-related diseases, and we evaluate how diet, medication exposure, living environment, geography, and disease burden shape reported microbiota signatures. We further organize microbial functions around metabolite-centered pathways, including short-chain fatty acids, trimethylamine N-oxide, phenylacetylglutamine, bile acids, tryptophan derivatives, and uremic microbial toxins. This framework clarifies when microbial alterations should be interpreted as biomarkers, plausible mediators, or candidate therapeutic targets. Finally, we discuss microbiota-targeted interventions, including diet, prebiotics, probiotics, fecal microbiota transplantation, postbiotics, metabolite-based therapeutics, and phage-based strategies, while emphasizing current limits in causal inference, safety, biomarker validation, and clinical implementation.
Zitieren
APA
Guo, C., Li, K., Wang, Z., & Zhao, Z. (2026). The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities. Cytotherapy and Longevity, 1(2), 1. https://doi.org/10.66729/cl202607005
Vancouver
Guo C, Li K, Wang Z, Zhao Z. The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities. Cytotherapy and Longevity. 2026;1(2):1. doi:10.66729/cl202607005
BibTeX
@article{Guo2026,
author = {Guo, Chenyu and Li, Kejun and Wang, Zhixing and Zhao, Zengren},
title = {The Gut Microbiota in Aging: From Compositional Shifts to Therapeutic Opportunities},
journal = {Cytotherapy and Longevity},
year = {2026},
volume = {1},
number = {2},
pages = {1},
doi = {10.66729/cl202607005}
}
EUVIMED